Onkologie. 2014:8(4):160-162

Immunotherapy in lung cancer

Leona Koubková
Pneumologická klinika 2. LF UK a FN Motol, Praha

In recent years, immunotherapy has proved to be a promising therapeutic modality in bronchogenic carcinoma as well. Of particular

interest is the blockade of immune checkpoints, which inhibit physiological immune mechanisms, and antigen-specific immunotherapy

with vaccines. Treatment with the blockade of immune checkpoints involves monoclonal antibodies blocking CTLA-4 (cytotoxic T-lymphocyte

antigen) and antibodies blocking the PD1 receptor (programmed cell death membrane protein) and its ligand PD-L1.

Keywords: bronchogenic carcinoma, blockade of immune checkpoints, vaccines

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koubková L. Immunotherapy in lung cancer. Onkologie. 2014;8(4):160-162.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Drake CG. Lipson EJ. Brahmer JR. Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology 2014; 11: 1(24-37). Go to original source... Go to PubMed...
    2. Tartour E. Zitvogel L. Lung cancer: Potential targets for immunotherapy. The Lancet Respiratory Medicine 2013; 1: 7(551-563). Go to original source... Go to PubMed...
    3. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31: 19(2396-2403). Go to original source... Go to PubMed...
    4. Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski MJ, Nawrocki S, Ciuleanu TE, Bosquee L, Perez JMT, Spira AI, Tremblay L, Nyman J, Ramlau R, Helwig C, Falk MH, Shepherd FA. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Journal of Clinical Oncology 2013; 31: 15(Suppl. 1). Go to original source... Go to PubMed...
    5. Sarah Declerck, Johan Vansteenkiste. Immunotherapy for Lung Cancer, Future Oncol. 2014; 10(1): 91-105. Go to original source... Go to PubMed...
    6. Liza C, Villaruz, Aparna Kalyan, Hassane Zarour, Mark A. Socinski. Immunotherapy in Lung Cancer. Transl Lung Cancer Res. 2014; 3(1): 2-14.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.